top of page
    • Sep 21

Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney

CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments of A1M are being developed for chronic kidney disease.




Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page